Stanford University School of Medicine, Stanford, CA 94305-5119, USA.
BMJ. 2019 Feb 25;364:l322. doi: 10.1136/bmj.l322.
Perinatal depression is a common disorder that has been associated with serious risks to mother and child. Recently, screening for depression in pregnant and postpartum women has increased, as has the development of new psychotherapy and non-drug treatment modalities. Matching patients to treatments can be challenging, and although research into personalized treatment of major depression in the general population has increased, no published guidelines focus on personalized treatment approaches to perinatal depression. In particular, guidelines on non-drug treatments are lacking. This review summarizes the evidence on personalized non-drug treatment of perinatal depression, how to incorporate patients' preferences, novel treatments under investigation, and the potential role of biomarkers in matching patients to treatment. The review provides recommendations for future research in personalized care of perinatal depression.
围产期抑郁症是一种常见疾病,与母婴的严重风险相关。最近,对孕妇和产后妇女的抑郁筛查有所增加,新的心理治疗和非药物治疗方法也有所发展。将患者与治疗方法相匹配具有挑战性,尽管针对一般人群中重度抑郁症的个性化治疗研究有所增加,但没有发表的指南专门针对围产期抑郁症的个性化治疗方法。特别是,缺乏关于非药物治疗的指南。这篇综述总结了围产期抑郁症的个性化非药物治疗的证据,如何纳入患者的偏好,正在研究的新治疗方法,以及生物标志物在将患者与治疗方法匹配中的潜在作用。该综述为围产期抑郁症个性化护理的未来研究提供了建议。